万佛帮看看这个粟米克隆35mm怎么样# PhotoGear - 摄影器材
g*3
1 楼
早在本版表达过自己的观点，非独立推荐人的推荐信如果写的好，也可以起很大作用。重点是他谈的都是就事实来说话，不是光说你牛啊，牛啊牛。所以这样非独立也就有power了，还有就是讲detail,这样贡献就很清晰了。我block了一些个人信息，但最大可能的保留了原文，基本到了可以被人肉的地步，但只要对后来人有用，被人肉了也在所不辞.在此也要special thank 我的老板，居然花了两个小时在办公室给我修改律师写好的推荐信。
------------------------------------------------------
Dear Sir or Madam:
This letter serves to express my strong support to Dr. Genegun, an immunologist who has made significant contributions to our understanding of immunosenescence --- the decline in immune responsiveness that occurs as part of aging. Dr. Genegun’s current research position is in the Department of AA at BB Medical School, where he has been a major researcher for many years. I am a Professor of AA at BB Medical School, having received a Ph.D. from CC and carried out my post-doctoral training at Havard Medical School.
Dr. Genegun is an expert on the development of DDD cells, immune cells that fight bacteria, viruses, and other pathogens in the body. A decline in DDD cells contributes to the decrease in immune responsiveness and increase in susceptibility to communicable diseases that occurs with age. Researchers have known for years that the body produces fewer DDD cells in old age, but the underlying cause has been unclear. Dr. Genegun caused a paradigm shift in the field by showing that aging does not affect the quality of the DDD stem cells. He proved that these cells are capable of maturation as they enter the EEE organ, where they undergo differentiation into fully developed DDD cells. In his influential FFF paper, Dr. Genegun showed that the decline in DDD cells results from alterations in the structural/environmental cells in the EEE organ. This study provided the first definitive answer to a long-debated question, leading the way for further work to stem the decline in DDD cell functionality with age. A loss of DDD cells also accounts for the vulnerability of AIDS patients to infections, and DDD cells are frequently compromised in cancer patients who have received treatment with radiation or chemotherapeutic drugs. Dr. Genegun’s current work, described below, is providing an avenue to remedy this problem.
Since coming to BB Medical School, Dr. Genegun has discovered that a key gene involved in cell survival, GGG, regulates a very rare population of the earliest DDD cell stem cells in the EEE organ. Increasing the expression of this gene expands the pool of these rare cells, which results in higher numbers of DDD cells at all subsequent stages of differentiation. By regulating GGG in these early precursors, one can expand the capacity for producing DDD cells. This can aid in the ability of the individual to produce immune cells with a diverse repertoire of specificities, resulting in an increased capability to respond to a wide variety of pathogenic substances and an enhanced ability to respond to vaccinations. This research is ground-breaking in that no other investigators have identified genes
that can increase the viability of these rare stem cells to allow for their expansion. Dr. Genegun presented this work at the American Association for Cancer Research Centennial Conference in 2007 in Singapore, and has two manuscripts, one of which under review for publication and the other of which is about to be submitted.
Dr. Genegun created a pure mouse strain containing an introduced human GGG gene for studying the role of this gene in the immune system. This strain is unique in that strains made using other genes in the same family have not been found to result in the enlargement of a normal EEE organ and often disrupt DDD cell development. The production of these mice has sped up our research at BB Medical School. In particular, we are using this strain to transfer bone marrow from mice expressing GGG into other animals in order to enhance the recovery of DDD cell development. These preclinical experiments will define conditions under which this approach can be used for therapeutic purposes in human patients. A variety of other investigators,including one at University of Wisconsin, Madison, and another at Universite Libre de Bruxelles, are using this strain in their research. In another noteworthy discovery, Dr. Genegun found that the effects of the GGG gene are seen in female but not male mice. This finding was so unexpected and novel that our laboratory received a supplement to our National Institutes of Health grant to allow us to fully follow it up. This observation will also be important in tailoring this approach for successful clinical application.
Dr. Genegun’s developments in DDD cell immunology have gained attention from researchers around the world. He has publications in international top-tier journals such as FFF (#18 in Field 1), HHH (#2 in Field 2), and III (#8 in Field 3), which have been independently cited over 50 times to date. This number of citations is well above the field’s average. A further indication of the impact of Dr. Genegun’s research is the fact that his papers have been cited in more than ten review articles, articles that summarize the most up-to-date findings on a specific topic. These review articles appeared in top journals, such as Current Opinion in Immunology (#6
in Immunlogy), Trends in Immunlogy (#11 in Immunlogy), and Experimental Gerontology (#1 in Geriatrics and Gerontology). His manuscript related to the role of GGG gene in early DDD stem cells received a favorable review from JJJ Journal and we have recently submitted a version amended in accordance with the reviewer’s suggestion.
BB Medical School is very fortunate to have Dr. Genegun on our research staff. He has brought world-class research to our laboratory and his contributions have sped up discoveries throughout the field. Should further discussion be required, please contact me through BB Medical School.
Sincerely,
KKK, PhD
BB Medical School
Department of AA
Phone: xxx-xxx-xxxx
Fax: xxx-xxx-xxxx
Email: x**[email protected]
------------------------------------------------------
Dear Sir or Madam:
This letter serves to express my strong support to Dr. Genegun, an immunologist who has made significant contributions to our understanding of immunosenescence --- the decline in immune responsiveness that occurs as part of aging. Dr. Genegun’s current research position is in the Department of AA at BB Medical School, where he has been a major researcher for many years. I am a Professor of AA at BB Medical School, having received a Ph.D. from CC and carried out my post-doctoral training at Havard Medical School.
Dr. Genegun is an expert on the development of DDD cells, immune cells that fight bacteria, viruses, and other pathogens in the body. A decline in DDD cells contributes to the decrease in immune responsiveness and increase in susceptibility to communicable diseases that occurs with age. Researchers have known for years that the body produces fewer DDD cells in old age, but the underlying cause has been unclear. Dr. Genegun caused a paradigm shift in the field by showing that aging does not affect the quality of the DDD stem cells. He proved that these cells are capable of maturation as they enter the EEE organ, where they undergo differentiation into fully developed DDD cells. In his influential FFF paper, Dr. Genegun showed that the decline in DDD cells results from alterations in the structural/environmental cells in the EEE organ. This study provided the first definitive answer to a long-debated question, leading the way for further work to stem the decline in DDD cell functionality with age. A loss of DDD cells also accounts for the vulnerability of AIDS patients to infections, and DDD cells are frequently compromised in cancer patients who have received treatment with radiation or chemotherapeutic drugs. Dr. Genegun’s current work, described below, is providing an avenue to remedy this problem.
Since coming to BB Medical School, Dr. Genegun has discovered that a key gene involved in cell survival, GGG, regulates a very rare population of the earliest DDD cell stem cells in the EEE organ. Increasing the expression of this gene expands the pool of these rare cells, which results in higher numbers of DDD cells at all subsequent stages of differentiation. By regulating GGG in these early precursors, one can expand the capacity for producing DDD cells. This can aid in the ability of the individual to produce immune cells with a diverse repertoire of specificities, resulting in an increased capability to respond to a wide variety of pathogenic substances and an enhanced ability to respond to vaccinations. This research is ground-breaking in that no other investigators have identified genes
that can increase the viability of these rare stem cells to allow for their expansion. Dr. Genegun presented this work at the American Association for Cancer Research Centennial Conference in 2007 in Singapore, and has two manuscripts, one of which under review for publication and the other of which is about to be submitted.
Dr. Genegun created a pure mouse strain containing an introduced human GGG gene for studying the role of this gene in the immune system. This strain is unique in that strains made using other genes in the same family have not been found to result in the enlargement of a normal EEE organ and often disrupt DDD cell development. The production of these mice has sped up our research at BB Medical School. In particular, we are using this strain to transfer bone marrow from mice expressing GGG into other animals in order to enhance the recovery of DDD cell development. These preclinical experiments will define conditions under which this approach can be used for therapeutic purposes in human patients. A variety of other investigators,including one at University of Wisconsin, Madison, and another at Universite Libre de Bruxelles, are using this strain in their research. In another noteworthy discovery, Dr. Genegun found that the effects of the GGG gene are seen in female but not male mice. This finding was so unexpected and novel that our laboratory received a supplement to our National Institutes of Health grant to allow us to fully follow it up. This observation will also be important in tailoring this approach for successful clinical application.
Dr. Genegun’s developments in DDD cell immunology have gained attention from researchers around the world. He has publications in international top-tier journals such as FFF (#18 in Field 1), HHH (#2 in Field 2), and III (#8 in Field 3), which have been independently cited over 50 times to date. This number of citations is well above the field’s average. A further indication of the impact of Dr. Genegun’s research is the fact that his papers have been cited in more than ten review articles, articles that summarize the most up-to-date findings on a specific topic. These review articles appeared in top journals, such as Current Opinion in Immunology (#6
in Immunlogy), Trends in Immunlogy (#11 in Immunlogy), and Experimental Gerontology (#1 in Geriatrics and Gerontology). His manuscript related to the role of GGG gene in early DDD stem cells received a favorable review from JJJ Journal and we have recently submitted a version amended in accordance with the reviewer’s suggestion.
BB Medical School is very fortunate to have Dr. Genegun on our research staff. He has brought world-class research to our laboratory and his contributions have sped up discoveries throughout the field. Should further discussion be required, please contact me through BB Medical School.
Sincerely,
KKK, PhD
BB Medical School
Department of AA
Phone: xxx-xxx-xxxx
Fax: xxx-xxx-xxxx
Email: x**[email protected]
